Angiotensin II (Ang II) increases adhesion molecules, cytokines and chemokines and exerts a proinflammatory effect on leucocytes, endothelial cells and vascular smooth muscle cells. Acting via the type 1 receptor, Ang II initiates an inflammatory cascade of reduced nicotinamide-adenine dinucleotide phosphate oxidase, reactive oxygen species (ROS) and nuclear factor-jB, which mediates transcription and gene expression and increases adhesion molecules and chemokines. An excess of ROS decreases nitric oxide bioavailability, causes endothelial dysfunction, and promotes atherosclerosis. Moreover, Ang II interrupts the anti-inflammatory effects of insulin. Together, these effects promote a prothrombotic state as well as plaque rupture. Ang II receptor blockers suppress mediators of inflammation, including ROS and C-reactive protein, and they increase expression of inhibitory jB (an inhibitor of nuclear factor-jB). These anti-inflammatory and antioxidative effects, which are probably due in part to unopposed stimulation of the Ang II type 2 receptor, may be beneficial in acute coronary syndromes and may also contribute to the prevention of type II diabetes mellitus, as insulin resistance is mediated by inflammatory processes.
Introduction
Angiotensin II (Ang II) is a powerful vasoconstrictor that induces the secretion of aldosterone and thereby the retention of sodium and water, which increases the circulating fluid volume and maintains normal blood pressure in hypotensive situations. In addition to its role in regulating blood pressure, Ang II has been shown to have important inflammatory and oxidative actions that are associated with atherosclerosis and acute coronary syndromes ( Figure 1 ).
Ang II is generated in the circulation (plasma) and in tissue -particularly the arterial wall. Endothelial cells are the major source of angiotensin-converting enzyme (ACE), which converts angiotensin I into Ang II. As Ang II is rapidly destroyed by angiotensinases (half-life of approximately 1 min), local renin-angiotensin systems probably play an important role in vascular-wall pathophysiology.
The two major classes of Ang II receptors are the type 1 (AT 1 ) and type 2 (AT 2 ) receptors. AT 2 receptors are not abundant in healthy adults; however, this class is upregulated in stressful conditions including vascular injury, myocardial infarction and heart failure. 1 The actions of Ang II mediated through AT 1 receptors -such as vasoconstriction and inflammation -oppose those mediated through AT 2 receptors, which include the release of nitric oxide (NO), an anti-inflammatory vasodilator that also reduces platelet aggregation and may facilitate the action of insulin. [2] [3] [4] [5] [6] [7] [8] [9] When AT 1 receptors are inactive or blocked, the actions mediated by AT 2 receptors are likely to dominate. 3 Thus, blockade of the renin-angiotensin system by angiotensin II receptor blockers (ARBs) may have dual effects: a decrease in vasoconstriction and aldosterone secretion accompanied by vasodilation mediated by an increase in NO.
Relation of Ang II to oxidative stress and inflammation
Ang II, acting via the AT 1 receptor, is likely to act as an inflammatory mediator through several mechan-isms. Ang II has been shown to exert a proinflammatory effect on leucocytes, endothelial cells and vascular smooth muscle cells. [10] [11] [12] [13] [14] [15] Ang II also provides a mitogenic stimulus for vascular smooth muscle cells. Studies in both endothelial and vascular smooth muscle cells have demonstrated that Ang II stimulates reduced nicotinamideadenine dinucleotide phosphate (NADPH) oxidase by acting on multiple subunits of this complex. In turn, NADPH oxidase is a key enzyme in the production of reactive oxygen species (ROS). [16] [17] [18] Inflammatory mediators stimulated by Ang II are listed in Table 1 .
Oxidative stress can be defined as an increase in ROS generation, and is a common feature of risk factors for atherosclerosis, including hyperlipidemia, hypertension and diabetes mellitus. The term ROS is a collective term that includes oxygencentred radicals (such as superoxide (O 2 K ) and hydroxyl (OH)) as well as some non-radical oxygen derivatives (such as hydrogen peroxide (H 2 O 2 ), singlet oxygen and hypochlorous acid (HOCL)). ROS are highly reactive and can rapidly oxidize lipids, proteins and nucleic acids; they are also able to damage cell membrane proteins. ROS-induced damage can fuse membrane lipid and proteins, thus hardening the cell membrane and exposing genetic material in the nucleus, which leaves the DNA vulnerable to mutation or destruction. ROS decrease the bioavailability of NO and cause endothelial dysfunction. 4 Indeed, ROS-mediated lipid peroxidation is a cardinal step in the initiation of atherosclerosis. 19 Detoxification is important to protect the body from ROS excess.
Thus, a critical balance exists between the generation and the detoxification of ROS in respiring cells of normal individuals. It is believed that the proinflammatory effects of Ang II are to a large extent mediated by increased oxidative stress.
The proinflammatory transcription factor, nuclear factor-kB (NF-kB), may be controlled by the redox status of the cell. 20 Indeed, inflammation at the cellular level can be described as an increase in NFkB in the nucleus and a concomitant decrease in its inhibitors IkBa and/or IkBb. NF-kB is a heterodimer, and usually consists of two proteins, a p65 (RelA) subunit and a p50 subunit (Figure 2 ). In the basal state, NF-kB is bound to its inhibitor protein IkB, which restricts NF-kB to the cytoplasm. Stimulation of cells by Ang II, cytokines (such as tumour necrosis factor-a (TNF-a) or interleukin (IL)-1), or endotoxin results in phosphorylation of IkB, unbinding of NF-kB from IkB and activation of NF-kB with its subsequent translocation into the nucleus. 21 This in turn induces the transcription of proinflammatory cytokines (such as TNF-a, IL-1 and IL-6), adhesion molecules (such as intercellular adhesion molecule (ICAM) and vascular cell adhesion molecule-1 (VCAM-1)), chemokines (such as monocyte chemoattractant protein-1 (MCP-1), IL-8 and macrophage inhibiting factor), matrix metalloproteinases (MMP-1 and MMP-9) and many other genes that regulate transcription, apoptosis and cell proliferation. Another transcription factor, activator protein-1 (AP-1), is also activated by Ang II. 12 Elevated plasma concentrations of C-reactive protein (CRP) are indicative of systemic inflammation. As CRP has recently been shown to promote MCP-1 and ICAM-1 expression and to suppress endothelial NO synthase expression, reduction of CRP may in itself exert a further anti-inflammatory effect. 22, 23 CRP has also been shown to increase myocardial infarct size in experimental animals. 24 A specific CRP receptor on endothelial cells has recently been identified. 25 It is therefore of interest that circulating CRP levels are decreased by ACE inhibitor (ACE-I) or ARB therapy (see below). Thus, Ang II increases adhesion molecules, cytokines and chemokines such as MMPs, tissue factor and plasminogen activator inhibitor-1 (PAI-1), acting through NF-kB and AP-1 activation, thereby predisposing to inflammation. This promotes a prothrombotic state as well as plaque rupture. 11, 14, 15 In addition, Ang II has been shown to interfere with insulin signal transduction and may thus contribute to insulin resistance. 26 Ang II may also inhibit the anti-inflammatory effect of insulin 27 and thus may exert a proinflammatory effect.
Ang II is found in large quantities in mononuclear cells. Levels of AT 1 receptors and ACE are increased in monocytes isolated from atherosclerotic lesions. 28 Ang II receptors are also found in platelets, endothelium and vascular smooth muscle cells. As platelets contain serotonin, norepinephrine and histamine in their dense bodies and CD40 in their a-granules, platelet activation and aggregation lead to the release of proinflammatory factors. Ang II also exerts a proaggregatory effect on blood platelets. [29] [30] [31] Another source of Ang II production is adipose tissue, which is now known to be involved in the production of inflammatory cytokines. Acting through the AT 1 receptor, Ang II has a regulatory function in adipose tissue, increasing the production of inflammatory mediators. In vitro, Ang II increases IL-6, IL-8 and PAI-1 production from cultured adipocytes by acting through the NF-kB pathway. 32, 33 Atherosclerosis is now considered to be an inflammatory disease. 34 Inflammatory mediators such as ICAM-1, VCAM-1 and MCP-1 initiate and promote the development of atheromas. Elevated CRP, IL-6 and PAI-1 levels are associated with acute coronary syndromes. As Ang II promotes inflammation, it is not surprising that Ang II is also a mediator of atherosclerosis. 35 It can therefore be expected that:
1. continued chronic overactivity of Ang II, which promotes inflammation, would have a proatherogenic effect, as atherosclerosis is an inflammatory process of the arterial wall. It follows that the suppression of Ang II activity would have an antiinflammatory and a potential antiatherogenic effect. 2. chronic overactivity of Ang II may also result in an insulin-resistant state, which may resolve following the suppression or blockade of angiotensin activity.
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ARBs and ACE-Is reduce inflammation and oxidative stress
Numerous clinical studies in subjects with a variety of cardiovascular conditions have shown that blockade of the renin-angiotensin system reduces inflammation and oxidative stress ( Table 2 ). In a study in normal subjects, we have shown that valsartan 160 mg daily for 7 days suppresses O 2 K generation by leucocytes and intranuclear NF-kB binding activity, and it increases IkB expression while decreasing plasma concentrations of CRP. 35 Studies with ARBs have demonstrated suppression of proinflammatory cytokines and oxidative stress in patients with hypertension. In a randomized, placebo-controlled, crossover trial, 37 candesartan 16 mg once daily given for 2 months to subjects with hypertension reduced plasma levels of malondialdhehyde (a product of lipid peroxidation) and improved the per cent flow-mediated dilator response to hyperaemia (from 5.17 to 6.22%). Plasma levels of MCP-1, TNF-a and PAI-1 were also reduced; however, there were no changes in plasma levels of CRP, MMP-9 antithrombin III, or fibrinogen. Changes in inflammatory mediators were not correlated with blood pressure reduction. Other studies in hypertensive patients showed that Figure 2 The NF-kB activation pathway. Activation of NF-kB involves the phosphorylation and subsequent degradation of the inhibitory protein IkB. The free NF-kB then passes into the nucleus, where it binds to promoter regions of genes for inflammatory proteins. Reproduced with permission from the Massachusetts Medical Society (N Engl J Med 1997; 336: 1066-1071).
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treatment with valsartan reduced lipopolysaccharidestimulated IL-1b production by peripheral blood monocytes 37 and that candesartan reduced inflammation and insulin resistance. 36 In subjects with the metabolic syndrome, treatment with irbesartan for 4 weeks showed an improvement in endothelium-dependent flowmediated vasodilation (measured in the brachial artery) and a decrease in the circulating concentrations of inflammatory mediators IL-6 and PAI-1 as well as the oxidative-stress marker 8-isoprostane. 38 These effects were independent of changes in blood pressure. Further, a study in patients with type II diabetes mellitus and hypertension showed reduced concentrations of circulating inflammatory mediators after treatment with either an ACE-I or an ARB. 39 The effects of ARBs on inflammatory mediators have also been assessed in patients with coronary artery disease (CAD). In internal mammary tissue samples from patients undergoing coronary artery bypass graft surgery, prior long-term ARB treatment significantly decreased gp91 phox (the limiting subunit of NADPH oxidase), thereby decreasing oxidative stress (and possibly inflammation, as ROS stimulate inflammatory mechanisms). 40 In a separate study, 41 normotensive patients with CAD received irbesartan for 4 months. The ARB reduced serum levels of VCAM-1 by 36%, TNF-a receptor II by 52% and O 2 K by 54% compared with baseline. Serum levels of CRP and the erythrocyte sedimentation rate were unchanged. Although patients with CAD had elevated levels of VCAM-1, O 2 K and TNF-a receptor II at baseline compared with controls (no CAD), there were no baseline differences in CRP levels or erythrocyte sedimentation rates between groups. Interestingly, whereas O 2 K decreased throughout the study, serum levels of VCAM-1 and TNF-a receptor II reached a maximum at 12 weeks. Irbesartan has also been shown to reduce lowdensity lipoprotein peroxidation and oxidative stress in patients with CAD. 42 Valsartan treatment lowered plasma CRP concentrations in the Valsartan Heart Failure Trial (ValHeFT). 43 These results confirmed and expanded on a smaller, shorter study of subjects with heart failure, 44 which showed that plasma levels of soluble ICAM-1, soluble VCAM-1, TNF-a and IL-6 fell after 2 weeks of therapy with candesartan. A recent study showed a reduction in CRP concentrations by Valsartan in hypertensive patients. 45 The effects of ARBs have also been studied in combination with statins or with other antihypertensive agents. In a study 46 of 112 CAD patients receiving a statin and with optimal low-density lipoprotein levels (o100 mg/dl), subjects were randomized to receive quinapril, irbesartan or placebo for 24 weeks; statin and aspirin therapy were continued. Both quinapril and irbesartan reduced serum IL-6 levels and decreased monocyte binding to a monoclonal antibody CD11b, indicating a reduction in the expression of the integrin CD11b, which is involved in monocyte adhesion to the endothelium. ARBs have also been shown to decrease coronary restenosis in CAD patients in conjunction with statins. 47 Clearly, therefore, ARBs exert an anti-inflammatory action both acutely (within 7 days) and over the long term. The suppression of oxidative stress and inflammation by ARBs probably contributes to the reductions in cardiovascular events demonstrated in clinical outcome studies. However, large-scale trials are still required to determine the effects of the longterm suppression of inflammation on cardiovascular diseases (CVDs) through the use of ARBs, as well as to determine how closely mediators of inflammation may correlate with CVD outcomes. In this context, it is relevant that ARBs also reduce the incidence of type II diabetes, as inflammation contributes to insulin resistance and Ang II interferes with insulin signal transduction. 48 Studies demonstrate that ACE-Is also decrease cardiovascular events and new-onset type II diabetes. 49, 50 As mentioned in Table 2 , ACE-Is also exert anti-inflammatory effects. In a randomized, placebocontrolled trial, ramipril given for 14 days after acute anterior wall myocardial infarction reduced PAI-1 levels by 44% compared with placebo. 51 However, in our shorter study showing reduced inflammation with valsartan in normotensive subjects, quinapril (40 mg daily for 1 week) did not demonstrate an anti-inflammatory effect. 35 It is possible that quinapril and other ACE-Is take longer to inhibit ACE in plasma and tissue than ARBs take to block Ang II activity. Of note, our study in normal subjects did not find an anti-inflammatory effect with simvastatin (80 mg) at 1 week. 35 As with ACEIs, it is possible that statins take longer to reduce inflammation.
ARBs may have a much greater potential to block the renin-angiotensin system than ACE inhibition, because an estimated 40% of Ang II is formed via non-ACE pathways (e.g., chymase) in humans. 52, 53 Furthermore, ARBs provide a theoretical additional advantage compared with ACE-Is by potentiating anti-inflammatory actions through AT 2 receptors. 1 ARBs cause a feedback increase in Ang II production, whereby unblocked AT 2 receptors are exposed to higher Ang II concentrations. 54 This may add to the protective effect of ARBs and may provide another explanation for our previous observations on the anti-inflammatory effects of valsartan. In this context, it is also important that AT 2 receptor deletion results in accelerated atherosclerosis in apolipoprotein E null mice. 55 There are intriguing parallels between the effects of ARBs and peroxisomal proliferator-activated receptor-g (PPAR-g) activators (known as thiazolidinediones (TZDs)) on reductions in insulin resistance and inflammation. TZDs are commonly used in the treatment of type II diabetes and polycystic ovary syndrome (an insulin-resistant state) because of their insulin-sensitizing effect. We have demonstrated that TZDs also have comprehensive antiinflammatory effects. 56, 57 In this regard, it is interesting that TZDs have been shown to attenuate the development of hypertension and improve endothelial dysfunction in Ang II-infused rats and to decrease AT 1 receptor expression in cultured vascular smooth muscle cells. 58, 59 TZDs also suppress atherosclerosis induction by Ang II in mice. 59 Conversely, some ARBs have modest PPAR-g activity 60 and increase the production of adiponectin (known to improve insulin sensitivity) from cultured adipocytes and obese Zucker rats. 61 This effect is mediated through AT 2 -receptor activation. A recent human study has demonstrated that valsartan induced an increase in the subnormal adiponectin concentrations in diabetic patients. 62 Concentrations of MCP-1, soluble VCAM and E-selectin in diabetic subjects also fell significantly but by small (about 10%) amounts. No decrease was recorded in the non-diabetic hypertensive patients. 62 Regardless of the possible mechanistic advantages of ARBs over ACE-Is, long-term trials such as Heart Outcomes Prevention Evaluation (HOPE) study and EUROPA have established the beneficial effects of ACE-I on cardiovascular end points. Although ARBs have a better side effect profile than ACE-I, ACE-I may remain the treatment of choice in the majority of patients as they are cheaper and have extensive data from randomized trials on their clinical efficacy.
Perspective
Because of their rapid anti-inflammatory and ROSsuppressive effects, ARBs may be useful agents for clinical situations requiring a rapid anti-inflammatory effect, such as acute myocardial infarction. In view of the absence of any significant side effects, this class of drugs may also have a potential use in the prevention of CVD in middle-aged persons in the general population. Another promising use could be in the prevention of type II diabetes mellitus in patients with obesity, insulin resistance and the metabolic syndrome. 63 Data from investigations of renin-angiotensin system blockade suggest that similar mechanistic studies need to be carried out for other classes of cardiovascular drugs that have been shown to improve atherosclerotic clinical outcomes. Such investigations would evaluate the possible antiinflammatory and anti-oxidant properties of these drugs. Further studies using combinations of drugs with these anti-inflammatory and antidiabetogenic properties would also be of interest. Search strategy: PubMed was used to review literature related to the effect of ACE inhibition and angiotensin II receptor blockade on inflammation. Keywords angiotensin, inflammation, ARB and ACE were used in the search. Search was limited to humans.
